132 related articles for article (PubMed ID: 29039546)
1. Antiproliferative effects of TSA, PXD‑101 and MS‑275 in A2780 and MCF7 cells: Acetylated histone H4 and acetylated tubulin as markers for HDACi potency and selectivity.
Androutsopoulos VP; Spandidos DA
Oncol Rep; 2017 Dec; 38(6):3412-3418. PubMed ID: 29039546
[TBL] [Abstract][Full Text] [Related]
2. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA
Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029
[TBL] [Abstract][Full Text] [Related]
3. Dynamics and regulation of lysine-acetylation during one-cell stage mouse embryos.
Matsubara K; Lee AR; Kishigami S; Ito A; Matsumoto K; Chi H; Nishino N; Yoshida M; Hosoi Y
Biochem Biophys Res Commun; 2013 Apr; 434(1):1-7. PubMed ID: 23567968
[TBL] [Abstract][Full Text] [Related]
4. Monitoring the effect of belinostat in solid tumors by H4 acetylation.
Marquard L; Petersen KD; Persson M; Hoff KD; Jensen PB; Sehested M
APMIS; 2008 May; 116(5):382-92. PubMed ID: 18452428
[TBL] [Abstract][Full Text] [Related]
5. Trichostatin A induces Trypanosoma cruzi histone and tubulin acetylation: effects on cell division and microtubule cytoskeleton remodelling.
de Oliveira Santos J; Zuma AA; de Luna Vitorino FN; da Cunha JPC; de Souza W; Motta MCM
Parasitology; 2019 Apr; 146(4):543-552. PubMed ID: 30421693
[TBL] [Abstract][Full Text] [Related]
6. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies.
Qian X; LaRochelle WJ; Ara G; Wu F; Petersen KD; Thougaard A; Sehested M; Lichenstein HS; Jeffers M
Mol Cancer Ther; 2006 Aug; 5(8):2086-95. PubMed ID: 16928830
[TBL] [Abstract][Full Text] [Related]
7. Effect of histone deacetylase inhibitor trichostatin A (TSA) on the microtubular system of Tetrahymena.
Kovács P; Pállinger E; Csaba G
Acta Biol Hung; 2007 Dec; 58(4):381-7. PubMed ID: 18277464
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
[TBL] [Abstract][Full Text] [Related]
9. Age-dependent response of lymphocytes in the induction of the linker histone variant, H1 degrees and histone H4 acetylation after treatment with the histone deacetylase inhibitor, trichostatin A.
Kypreou KP; Sourlingas TG; Sekeri-Pataryas KE
Exp Gerontol; 2004 Apr; 39(4):469-79. PubMed ID: 15050280
[TBL] [Abstract][Full Text] [Related]
10. Differential protein acetylation induced by novel histone deacetylase inhibitors.
Glaser KB; Li J; Pease LJ; Staver MJ; Marcotte PA; Guo J; Frey RR; Garland RB; Heyman HR; Wada CK; Vasudevan A; Michaelides MR; Davidsen SK; Curtin ML
Biochem Biophys Res Commun; 2004 Dec; 325(3):683-90. PubMed ID: 15541343
[TBL] [Abstract][Full Text] [Related]
11. Liposomes loaded with histone deacetylase inhibitors for breast cancer therapy.
Urbinati G; Marsaud V; Plassat V; Fattal E; Lesieur S; Renoir JM
Int J Pharm; 2010 Sep; 397(1-2):184-93. PubMed ID: 20603204
[TBL] [Abstract][Full Text] [Related]
12. PXD101 analogs with L-phenylglycine-containing branched cap as histone deacetylase inhibitors.
Li J; Li X; Wang X; Hou J; Zang J; Gao S; Xu W; Zhang Y
Chem Biol Drug Des; 2016 Oct; 88(4):574-84. PubMed ID: 27235003
[TBL] [Abstract][Full Text] [Related]
13. C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivo.
Zhu QY; Wang Z; Ji C; Cheng L; Yang YL; Ren J; Jin YH; Wang QJ; Gu XJ; Bi ZG; Hu G; Yang Y
Cell Death Dis; 2011 Jan; 2(1):e117. PubMed ID: 21368888
[TBL] [Abstract][Full Text] [Related]
14. Effects of trichostatin A, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells.
Park H; Lee YJ; Kim TH; Lee J; Yoon S; Choi WS; Myung CS; Kim HS
Int J Mol Med; 2008 Nov; 22(5):605-11. PubMed ID: 18949380
[TBL] [Abstract][Full Text] [Related]
15. ARHGEF3 controls HDACi-induced differentiation via RhoA-dependent pathways in acute myeloid leukemias.
D'Amato L; Dell'Aversana C; Conte M; Ciotta A; Scisciola L; Carissimo A; Nebbioso A; Altucci L
Epigenetics; 2015; 10(1):6-18. PubMed ID: 25494542
[TBL] [Abstract][Full Text] [Related]
16. Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases.
Brush MH; Guardiola A; Connor JH; Yao TP; Shenolikar S
J Biol Chem; 2004 Feb; 279(9):7685-91. PubMed ID: 14670976
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of HDAC inhibitors on PPN oscillatory activity in vivo.
Bisagno V; Bernardi MA; Sanz Blasco S; Urbano FJ; Garcia-Rill E
Neuropharmacology; 2020 Mar; 165():107922. PubMed ID: 31923766
[TBL] [Abstract][Full Text] [Related]
18. Multiple histone deacetylases and the CREB-binding protein regulate pre-mRNA 3'-end processing.
Shimazu T; Horinouchi S; Yoshida M
J Biol Chem; 2007 Feb; 282(7):4470-4478. PubMed ID: 17172643
[TBL] [Abstract][Full Text] [Related]
19. Possible mechanism of action of the histone deacetylase inhibitors for the induction of differentiation of HL-60 clone 15 cells into eosinophils.
Ishihara K; Hong J; Zee O; Ohuchi K
Br J Pharmacol; 2004 Jul; 142(6):1020-30. PubMed ID: 15210580
[TBL] [Abstract][Full Text] [Related]
20. Differential sensitivity of human leukemic cell lines to the histone deacetylase inhibitor, trichostatin A.
Ninios YP; Sekeri-Pataryas KE; Sourlingas TG
Leuk Res; 2010 Jun; 34(6):786-92. PubMed ID: 19782399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
